Melissa Trombetta

ITT Corp. manufactures engineered critical components and customized solutions for the energy, transportation, and industrial markets. It operates through the following segments: Industrial Process, Motion Technologies, Interconnect Solutions, and Control Technologies. The Industrial Process segment manufactures engineered fluid process equipment which serves various customers in global infrastructure industries such as oil and gas, mining, power generation, chemical and other process markets and also provides aftermarket services. The Motion Technologies segment manufactures brake pads, shock absorbers, and damping technologies for the global automotive, truck, trailer, and public bus and rail transportation markets. The Interconnect Solutions segment manufactures a wide range of highly specialized connector products that make it possible to transfer signal and power in various electronic devices that are utilized in aerospace and defense; industrial and transportation; oil and gas; and medical markets. The Control Technologies segment manufactures specialized equipment which includes actuation, valves, switches, vibration isolation, custom-energy absorption, and regulators for the aerospace and defense, and industrial markets. The company was founded by Sosthenes Behn and Hernand Behn in 1920 and is headquartered in White Plains, NY.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA.